Service de Dermatologie, Hôpital Saint-Eloi, CHU de Montpellier, Université Montpellier I, Montpellier, France.
Dermatology. 2011;222(2):123-7. doi: 10.1159/000326112. Epub 2011 Apr 5.
Sweet's syndrome is a neutrophilic dermatosis characterized by fever, an elevated neutrophil count, and painful erythematous cutaneous lesions. Histopathological analysis reveals a neutrophilic dermal infiltrate. Systemic corticosteroid therapy remains the mainstay of treatment. We report the case of a 66-year-old male patient who had a 5-year history of Sweet's syndrome refractory to various conventional treatments. Anti-interleukin-1 receptor antagonist anakinra was initiated and this resulted in a dramatic clinical and biological improvement. Anakinra is a promising treatment for neutrophilic dermatoses and sheds light on the interleukin-1/inflammasome pathway as central in the physiopathology of neutrophilic dermatosis.
Sweet 综合征是一种中性粒细胞皮肤病，其特征为发热、中性粒细胞计数升高和疼痛性红斑性皮肤损伤。组织病理学分析显示中性粒细胞真皮浸润。全身性皮质类固醇治疗仍然是主要的治疗方法。我们报告了一例 66 岁男性患者，他患有 Sweet 综合征，对各种常规治疗均无反应，已有 5 年病史。开始使用抗白细胞介素-1 受体拮抗剂阿那白滞素，结果临床和生物学均显著改善。阿那白滞素是一种治疗中性粒细胞皮肤病的有前途的药物，并揭示了白细胞介素-1/炎症小体途径在中性粒细胞皮肤病的病理生理学中的核心作用。
